Article Details
Retrieved on: 2024-04-07 05:49:42
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
D., VP of Biocytogen, CEO and CMO of Eucure Biopharma. “As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very ...
Article found on: www.theglobeandmail.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here